NRG1 recombinant protein: a key ligand in the ErbB receptor signaling network, neural repair, and tumorigenesis

Author: Senior Product Manager of UA Views：18

This article focuses on the molecular characteristics and biological functions of neuregulin 1 (NRG1), systematically elaborating its molecular mechanism as a member of the epidermal growth factor family in mediating cell signal transduction through ErbB receptor tyrosine kinases, analyzing the dual role of NRG1 in peripheral nervous system development, nerve repair, and epithelial-derived tumorigenesis, and exploring the clinical significance of NRG1 gene fusion as a carcinogenic driver and its detection strategies.

Recent Advances
Product Information

Recent Advances

NRG1 Recombinant Protein: A Key Ligand in the ErbB Receptor Signaling Network, Neural Repair, and Tumorigenesis

Summary: This article focuses on the molecular characteristics and biological functions of neuregulin 1 (NRG1), systematically elaborating the molecular mechanism by which it mediates cellular signal transduction through ErbB receptor tyrosine kinases as a member of the epidermal growth factor family, analyzing the dual roles of NRG1 in peripheral nervous system development, neural repair, and epithelial-derived tumorigenesis, and discussing the clinical significance of NRG1 gene fusions as oncogenic drivers and their detection strategies.

I. Molecular Structure and Family Localization of NRG1.

Neuregulin 1 (NRG1), also known as neu differentiation factor or heregulin-β, has a molecular weight of approximately 44 kDa. The NRG1 protein domains mainly include: the inner region, transmembrane domain, juxtamembrane sequence, extracellular EGF-like domain, immunoglobulin-like domain, and amino acid sequence. NRG1 is a member of the epidermal growth factor family and is the primary ligand for ErbB family receptors. NRG1 isoforms can signal in a paracrine, autocrine, or endocrine manner, playing a fundamental role in peripheral nervous system development and neural repair, suggesting that NRG1 therapy may improve functional outcomes after injury. This indispensable physiological function in the nervous system has made NRG1 a growth factor of great interest in neural repair research.

II. The Receptor System and Signal Transduction Mechanism of NRG1.

The receptors for NRG1 are ErbB family transmembrane receptor tyrosine kinases, composed of four surface receptors: ERBB1/EGFR, ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4, among which the epidermal growth factor receptor is the most prominent representative. However, ErbB family members themselves lack a kinase domain and need to combine with other ErbB family members to form heterodimers in order to bind NRG1 and form the ErbB receptor/NRG1 complex. After NRG1 binds to ErbB3/HER3, it can recruit ErbB2/HER2 to form a heterodimeric complex with high kinase activity, activating downstream signaling pathways such as PI3K/AKT and MAPK, and regulating cell proliferation, differentiation, and survival. This signal transduction mode dependent on heterodimerization determines the unique ligand status of NRG1 in the ErbB signaling network.

III. Physiological Functions of NRG1 in Nervous System Development and Repair.

NRG1 plays a fundamental role in peripheral nervous system development and neural repair. During embryonic development, NRG1 regulates Schwann cell proliferation, migration, and myelination through the ErbB2/ErbB3 signaling axis, and is a key regulatory factor in peripheral nerve myelin development. In the adult nervous system, NRG1 participates in regulating the repair process after nerve injury, promoting Schwann cell dedifferentiation and re-entry into a proliferative state, providing the necessary microenvironmental support for axon regeneration. These physiological functions indicate that exogenous NRG1 recombinant protein may improve functional recovery after nerve injury, providing a potential intervention strategy for the treatment of peripheral nerve injury and demyelinating diseases.

IV. NRG1 Gene Fusions and the Development of Epithelial-Derived Tumors.

In-frame NRG1 gene fusions can activate and retain the EGF-like domain of the NRG1 protein, enabling it to bind to ErbB3/HER3. ErbB family receptors have oncogenic effects and are often overexpressed in epithelial-derived tumors such as lung cancer, breast cancer, and colorectal cancer, participating in the regulation of related signaling pathways, leading to cell proliferation or differentiation, and ultimately resulting in cancer development. NRG1 gene fusions are relatively rare and are potential oncogenic drivers in certain solid tumors. The literature has evaluated the incidence of NRG1 fusions across multiple tumor types and described the corresponding fusion partners. This discovery has made NRG1 fusions another molecular target with precision therapeutic potential following other classic oncogenic fusions.

V. Detection Methods and Clinical Significance of NRG1 Fusion Genes.

According to the literature, the detection of NRG1 fusion genes is divided into protein-level detection and molecular-level detection. At the protein level, immunohistochemistry, due to its methodological characteristics, can serve as a screening tool with a broad detection range and rapid result output; its disadvantage is that it cannot detect the precise fusion partner.

At the molecular level, there are four detection methods. Fluorescence in situ hybridization (FISH) is the most feasible molecular detection method and is also the gold standard for detecting break-apart/fusion events; break-apart probes can detect fusions with unknown partner genes, making break-apart probes the preferred choice for detection. On the other hand, FISH detection does not have high requirements for the cell content in samples; interpretation can be performed with more than 50 tumor cells present in the sample. Anchored multiplex PCR technology is suitable for FFPE specimens with low nucleic acid content and can effectively detect gene rearrangements, single nucleotide mutations, insertions, deletions, and copy number variations; its disadvantage is that it has very high requirements for sample quality. Next-generation sequencing can detect whether small fragments have abnormalities, but it depends on panel design and presents certain difficulties. Targeted RNA sequencing can be performed at the RNA level and is likewise unaffected by intron segment length; its disadvantage is also the high requirement for sample quality, and specimens preserved for a long time may fail to yield the expected detection results. The rational combined use of these methods is key to improving the detection rate of NRG1 fusions.

VI. Conclusion.

In NRG1-related basic research and drug development, high-quality recombinant NRG1 protein is a core tool for dissecting its binding mechanism with ErbB receptors and evaluating targeted drug activity. In response to the needs of NRG1 functional research and ErbB signaling pathway exploration, UniA provides NRG1/Heregulin-β1 Protein, Human. This product is suitable for application scenarios such as binding activity analysis of NRG1 with ErbB3/ErbB2 receptors, research on ErbB receptor heterodimerization and downstream signaling pathway mechanisms, in vitro screening and evaluation of antibody drugs targeting the NRG1-ErbB axis, and functional research on NRG1 in neural repair and tumorigenesis.

As a core ligand for ErbB receptors in the epidermal growth factor family, NRG1, by virtue of its signal transduction mechanism mediated through ErbB3/ErbB2 heterodimers, its fundamental physiological functions in peripheral nervous system development and neural repair, and its oncogenic role in gene fusion-driven epithelial-derived tumorigenesis, has become an important molecule connecting neurobiology and precision tumor therapy. From the key regulation of NRG1 in Schwann cell myelination to the clinical discovery of gene fusions as rare oncogenic drivers, from protein-level immunohistochemistry screening to the combined application of multiple molecular-level detection methods, NRG1 continues to drive in-depth development in the fields of neural repair and targeted tumor therapy. NRG1/Heregulin-β1 Protein, Human provides reliable tool support for mechanistic research on the NRG1 signaling network and targeted drug development, and will continue to facilitate innovative exploration in the fields of neurobiology and precision tumor therapy.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next